Crohn's disease trials in Japan

In Japan 22 Also abroad 422

22 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
Where
Abiko, Bunkyō, Chūō, Fukuoka, Fukuyama, Ginowan, Hamamatsu, Hirakata, Hiroshima, Hitachi, Kagoshima, Kamakura, Kanazawa, Kashiwa, Kawagoe, Kawasaki, Kofu, Kumamoto, Kurume, Kyoto, Maebashi, Minato, Minato-ku, Mitaka, Mitato, Nagakute, Nagoya, Nishinomiya, Okayama, Osaka, Saga, Sakura, Sapporo, Sendai, Shimizu, Shinjuku, Shiwa-gun, Tokyo, Toyama, Tsu, Tsuchiura, Tsukuba, Yamagata, Yokohama
Age
16 years to 80 years
People
1,200 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06430801 · EU 2023-508636-61-00
Phase 2Taking people
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
Where
Asahikawa, Bunkyō, Chikushino-shi, Kashiwa-shi, Kobe, Kofu, Nagasaki, Nara, Osaka, Saga, Saitama, Saitama-Ken, Sakura, Sapporo, Tokyo
Age
18 years to 85 years
People
385 worldwide
Run by
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
See details and how to joinNCT06226883 · EU 2023-508158-24-00
Phase 3Taking people
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
Where
Hirosaki, Kagoshima, Kashiwa-shi, Kobe, Saga, Sendai, Setagaya-Ku, Tokyo, Tsu, Ube, Yokohama
Age
2 years to 17 years
People
120 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT05923073 · EU 2023-504735-41-00
Phase 3Taking people
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
Where
Fuchū, Kanazawa, Kobe, Kumamoto, Matsumoto, Saga, Yokohama
Age
3 years to 64 years
People
196 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06663332 · EU 2023-509560-16-00
Phase 2/3Taking people
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
Where
Chiba, Fukui-shi, Gamagōri, Hamamatsu, Higashiibaraki-gun, Hiroshima, Kagawa, Kagoshima, Kanazawa, Kashiwa, Kawagoe, Kitakyushu, Kumamoto, Kurume, Mitaka, Miyagi, Nagakute, Nagasaki, Nishinomiya-shi, Okinawa, Osaka, Saga, Sakura, Sapporo, Sendai, Shinjuku-ku, Shinjuku-Ku, Sunto-gun
Age
18 years and over
People
1,092 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07196722 · EU 2025-521382-27-00
Phase 3Taking people
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
Where
Bunkyō City, Hamamatsu, Hirosaki, Kagoshima, Kashiwa, Kobe, Kumamoto, Minatoku, Mitaka, Nagoya, Nishinomiya, Osaka, Sapporo, Sendai, Shimizu, Takamatsu, Tokyo, Yamanashi, Yokohama
Age
18 years and over
People
460 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07577843 · EU 2026-525922-39-00
Phase 2Taking people
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
Where
Chiba, Fukuoka, Hamamatsu, Hirakata, Minato, Mitaka, Morioka, Nishinomiya, Sapporo, Sendai, Takatsuki-shi, Tokyo, Toyama
Age
18 years to 75 years
People
268 worldwide
Run by
Takeda
See details and how to joinNCT06233461 · EU 2023-506704-14-00
Phase 2Taking people
A Study to Investigate Efficacy and Safety of Brivekimig in Participants With Crohn's Disease
Where
Bunkyō City, Hamamatsu, Hirosaki, Kashiwa, Morioka, Nishinomiya, Ōita
Age
18 years to 75 years
People
99 worldwide
Run by
Sanofi
See details and how to joinNCT06958536 · EU 2024-517016-30-00
Phase 2Taking people
Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
Where
Kure
Age
18 years to 75 years
People
2,000 worldwide
Run by
AbbVie
See details and how to joinNCT07697456 · EU 2026-525959-86-00
Phase 4Taking people
Risankizumab for Refractory Perianal Fistulizing Crohn's Disease
Where
Nishinomiya, Shinjuku-Ku, Yokohama
Age
15 years and over
People
25
Run by
Yuki Horio
See details and how to joinNCT07872449
Phase 3Taking people
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
Where
Asahikawa, Bunkyō City, Chikushino-shi, Fukuoka, Hachiōji, Isehara, Isesaki, Kagoshima, Kamakura, Kashiwa, Kitakyushu, Kobe, Kōriyama, Kumamoto, Kurume, Maebashi, Minato, Mitaka, Nagakute, Nagoya, Nishinomiya, Okayama, Osaka, Saga, Sagamihara, Sakura, Sapporo, Sendai, Shimotsuga-gun, Shinjuku, Shiwa-gun, Shizuoka, Toyama, Toyohashi, Tsu, Yokohama
Age
16 years to 80 years
People
980 worldwide
Run by
Sanofi
See details and how to joinNCT07184931
Phase 3Taking people
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
Where
Kamakura, Nishinomiya, Tsu
Age
16 years to 80 years
People
751 worldwide
Run by
Sanofi
See details and how to joinNCT07184944
Phase 3Taking people
A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
Where
Bunkyo-ku, Fuchu-shi, Izumi-Shi, Kashiwa-shi, Kumamoto, Kurume-shi, Maebashi, Ōbu, Saitama-shi, Setagaya City
Age
2 years to 17 years
People
110 worldwide
Run by
AbbVie
See details and how to joinNCT05995353 · EU 2022-502050-14-00
Phase 3Taking people
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
Where
Aichi, Aomori, Asahikawa-shi, Asahikawa-Shi, Chiba, Chikushino-shi, Ehime, Fukui, Fukuoka, Hiroshima, Hokkaido, Hyōgo, Ishikawa, Kagawa, Kagoshima, Kanagawa, Kumamoto, Miyagi, Nagasaki, Okayama, Osaka, Saga, Sendai, Shizuoka, Takamatsu, Tokyo, Toyama, Wakayama, Yamagata, Yamanashi
Age
16 years to 80 years
People
600 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06819878 · EU 2024-513053-69-00
Phase 3Taking people
A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
Where
Bunkyo-ku, Kurume-shi, Setagaya-Ku
Age
2 years to 17 years
People
70 worldwide
Run by
Takeda
See details and how to joinNCT06405087 · EU 2023-508804-39-00
Phase 3Taking people
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
Where
Bunkyō, Bunkyō City, Kashiwa, Kobe, Tokyo, Yokohama
Age
2 years to 19 years
People
150 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT04844606
Phase 3Taking people
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
Where
Bunkyō City, Hirosaki, Kagoshima, Kashiwa-shi, Kobe, Saga, Sendai, Setagaya-Ku, Tsu, Ube, Yokohama
Age
2 years to 17 years
People
90 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT05509777 · EU 2024-511472-32-00
Phase 3Taking people
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
Where
Bunkyo-ku, Kurume, Setagaya-Ku
Age
2 years to 17 years
People
70 worldwide
Run by
Takeda
See details and how to joinNCT06100289 · EU 2023-503188-40-00
Phase 3Taking people
A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
Where
Bunkyo-ku, Hidaka, Kumamoto, Kurume-shi, Setagaya-Ku
Age
2 years to 17 years
People
240 worldwide
Run by
Takeda
See details and how to joinNCT05442567 · EU 2023-509046-36-00
Phase 3Taking people
A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
Where
Bunkyo-ku, Kumamoto, Kurume-shi, Setagaya-Ku
Age
2 years to 17 years
People
120 worldwide
Run by
Takeda
See details and how to joinNCT04779320 · EU 2023-509045-13-00
No phaseTaking people
An Observational Study to Assess Change in Disease Activity and Adverse Events in Adolescent and Adult Participants With Moderate to Severe Active Crohn's Disease (CD) in Japan
Where
Ageo, Ako, Anjo-shi, Bunkyo-ku, Chikushino-shi, Chuo-ku, Fukui, Fukuoka, Fukushima, Fukuyama-shi, Gifu, Ginowan-shi, Hachinohe, Hamamatsu, Handa, Hatsukaichi, Himeji, Himeji-shi, Hiroshima, Ibaraki-shi, Isehara, Itami, Kagoshima, Kakamigahara-shi, Kamakura-shi, Kanazawa, Kashiwa-shi, Kawagoe, Kitakyushu, Kitakyushu-shi, Kobe, Kochi, Kofu, Koganei-shi, Kōriyama, Kumamoto, Kurume, Kurume-shi, Kyoto, Matsuyama, Mibu, Minato-ku, Moriguchi, Nagakute, Nagano, Nagasaki, Nagoya, Naha, Nishinomiya-shi, Odawara-shi, Ōita, Onga-gun, Ono, Osaka, Saga, Sagamihara-shi, Saitama, Saitama-shi, Sakai, Sapporo, Setagaya-ku, Shibuya-ku, Shinjuku-ku, Shizuoka, Sizuoka-shi, Sumida-ku, Sunto-gun, Takamatsu, Takatsuki, Tokorozawa, Tokyo, Toyama, Toyohashi, Toyonaka, Toyota-shi, Tsu, Tsukuba, Ube, Utsunomiya, Uwajima, Wakayama, Yamagata, Yamaguchi, Yokkaichi-shi, Yokohama
Age
15 years and over
People
240
Run by
AbbVie
See details and how to joinNCT06023030
No phaseTaking people
A Survey of Darvadstrocel in People With Crohn's Disease
Where
Tokyo
Age
20 years and over
People
275
Run by
Takeda
See details and how to joinNCT05113095